Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.59 |
| ▸ | CALCRL | Q16602 | 3/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL261346 | 0.83 | CALCRL (0.49) | ALDH1A1CALCRLKDM4E | |
| Lithium Ion SCHEMBL259962 | 0.81 | CALCRL (0.49) | ALDH1A1CALCRLKDM4ESMN1; SMN2 | |
| SCHEMBL261384 | 0.77 | ALDH1A1 (0.59) | ALDH1A1ADORA2BNPSR1LMNASMN1; SMN2 | |
| SCHEMBL12965113 | 0.75 | CALCRL (0.39) | ALDH1A1CALCRLNPSR1LMNAKDM4E | |
| SCHEMBL280579 | 0.74 | CALCRL (0.45) | ALDH1A1CALCRLDRD2 | |
| SCHEMBL261309 | 0.71 | CALCRL (0.50) | ALDH1A1CALCRLKDM4ESMN1; SMN2 | |
| SCHEMBL261740 | 0.71 | CALCRL (0.41) | ALDH1A1CALCRLLMNASMN1; SMN2 | |
| SCHEMBL1420993 | 0.71 | ALDH1A1 (0.63) | ALDH1A1LMNAKDM4ESMN1; SMN2MAPT | |
| SCHEMBL261408 | 0.71 | CALCRL (0.39) | ALDH1A1CALCRLNPSR1LMNAKDM4E | |
| SCHEMBL261185 | 0.70 | CALCRL (0.51) | ALDH1A1CALCRLKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163752-B2 | Tricyclic anilide heterocyclic CGRP receptor antagonists | Merck, Sharp & Dohme Corp. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8133891-B2 | Tricyclic anilide spirolactam CGRP receptor antagonists | Merck, Sharp & Dohme Corp. (US) | 2012-03-13 | — | — | US | disclosed |
| US-7968540-B2 | Spirohydantoin tricyclic CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7947677-B2 | Spirolactam tricyclic CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7750010-B2 | Tricyclic anilide spirohydantion CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20100160334-A1 | TRICYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-06-24 | — | — | US | disclosed |
| US-20100137328-A1 | TRICYCLIC ANILIDE HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-06-03 | — | — | US | disclosed |
| US-7696192-B2 | Tricyclic anilide spirolactam CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-04-13 | — | — | US | disclosed |
| US-20090281080-A1 | Spirohydantoin Tricyclic CGRP Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-11-12 | — | — | US | disclosed |
| US-20090221535-A1 | IMMUNOGENIC COMPOSITIONS FOR GRAM POSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE | MERCK SHARP & DOHME LLC | 2009-09-03 | — | — | US | disclosed |
| US-20090105219-A1 | Spirolactam Tricyclic CGRP Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-04-23 | — | — | US | disclosed |
| US-20080214511-A1 | Tricyclic Anilide Spirolactam Cgrp Receptor Antagonists | MERCK & CO., INC. (US) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214511-A1 | Tricyclic Anilide Spirolactam Cgrp Receptor Antagonists | BDKRB1, CALCRL, BDKRB2 | ALDH1A1 1122/4885CALCRL 2/4885ALOX15 1617/4885 |
| US-20100160334-A1 | TRICYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | BDKRB1, CALCRL, BDKRB2 | ALDH1A1 1122/4885CALCRL 2/4885ALOX15 1617/4885 |
| US-20100137328-A1 | TRICYCLIC ANILIDE HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | BDKRB1, CCKBR, BDKRB2 | ALDH1A1 1622/4885CALCRL 4/4885ALOX15 1147/4885 |
| US-20090105219-A1 | Spirolactam Tricyclic CGRP Receptor Antagonists | BDKRB1, CALCRL, BDKRB2 | ALDH1A1 962/4885CALCRL 2/4885ALOX15 1517/4885 |
| US-20090281080-A1 | Spirohydantoin Tricyclic CGRP Receptor Antagonists | BDKRB1, BDKRB2, CCKBR | ALDH1A1 1140/4885CALCRL 4/4885ALOX15 1782/4885 |
| US-20090221535-A1 | IMMUNOGENIC COMPOSITIONS FOR GRAM POSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE | C1R, CALCB, MRGPRX2 | ALDH1A1 4839/4885CALCRL 7/4885ALOX15 2694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.